ERBB2 and triple-negative breast carcinoma: Approximately 10–20% of BCs do not express estrogen and progesterone receptors and lack amplification/overexpression of the human epidermal growth factor 2 receptor (HER2) [2–4]; therefore, they are known as triple-negative breast cancers (TNBCs) and constitute an aggressive histologic subtype.